The Haloperidol Injection, cataloged under National Stock Number 6505-01-694-5455, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Mylan Pharmaceuticals Inc. Government technical data includes 4 specifications, cited from the U.S. Government catalog. The record lists 3 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 2 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: PG.
| Parameter | Value |
|---|---|
| NSN | 6505-01-694-5455 |
| Primary Part Number | NDC67457-0426-12 |
| Item Name | Haloperidol Injection |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Mylan Pharmaceuticals Inc |
| Status | ACTIVE |
| Administration | INTRAMUSCULAR |
| Primary Container Content Quantity | 1.0 MILLILITERS |
| Primary Container Type | VIAL |
| Total Primary Container Quantity | 25 |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | PG |
| Part Number | Manufacturer |
|---|---|
| 10026998 | Amerisourcebergen Drug Corp Dba Amerisourcebergen Drug Corp Div Corporate Office (USA) |
| NDC67457-0426-12 PRIMARY | Mylan Pharmaceuticals Inc (USA) |
| NDC63323-0474-01 PRIMARY | Fresenius Kabi, Llc (USA) |
| Reference | Meaning |
|---|---|
| 6505NCM216968 | 5/1 Secondary reference Defense Medical Standardization Board |
| 1590646 | 5/1 Secondary reference U.S. Government activity |
NSN 6505-01-694-5455 is a Haloperidol Injection, manufactured by Mylan Pharmaceuticals Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-694-5455 has 3 manufacturer part numbers on file: 10026998 (Amerisourcebergen Drug Corp Dba Amerisourcebergen Drug Corp Div Corporate Office), NDC67457-0426-12 (Mylan Pharmaceuticals Inc), NDC63323-0474-01 (Fresenius Kabi, Llc).
Key specifications for NDC67457-0426-12: Administration: INTRAMUSCULAR; Primary Container Content Quantity: 1.0 MILLILITERS; Primary Container Type: VIAL; Special Features: HALOPERIDOL 5 MG/ML INJECTION SOLUTION SUPPLIED AS 5MG PER ML, 1ML FILL IN A 2ML VIAL. STORE AT 20 TO 25C (68 TO 77F) USP CONTROLLED ROOM TEMPERATURE. DO NOT FREEZE. PROTECT FROM LIGHT.. 4 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.